179 related articles for article (PubMed ID: 31041833)
1. Rapid characterization of structural and functional similarity for a candidate bevacizumab (Avastin) biosimilar using a multipronged mass-spectrometry-based approach.
Brown KA; Rajendran S; Dowd J; Wilson DJ
Drug Test Anal; 2019 Aug; 11(8):1207-1217. PubMed ID: 31041833
[TBL] [Abstract][Full Text] [Related]
2. Epitope Mapping for a Preclinical Bevacizumab (Avastin) Biosimilar on an Extended Construct of Vascular Endothelial Growth Factor A Using Millisecond Hydrogen-Deuterium Exchange Mass Spectrometry.
Brown KA; Lento C; Rajendran S; Dowd J; Wilson DJ
Biochemistry; 2020 Aug; 59(30):2776-2781. PubMed ID: 32672953
[TBL] [Abstract][Full Text] [Related]
3. LC-MS based case-by-case analysis of the impact of acidic and basic charge variants of bevacizumab on stability and biological activity.
Singh SK; Kumar D; Malani H; Rathore AS
Sci Rep; 2021 Jan; 11(1):2487. PubMed ID: 33514790
[TBL] [Abstract][Full Text] [Related]
4. Part 2: Physicochemical characterization of bevacizumab in 2 mg/mL antibody solutions as used in human i.v. administration: Comparison of originator with a biosimilar candidate.
Arvinte T; Palais C; Poirier E; Cudd A; Rajendran S; Brokx S; Dowd J
J Pharm Biomed Anal; 2019 Nov; 176():112802. PubMed ID: 31446298
[TBL] [Abstract][Full Text] [Related]
5. Comparative higher-order structure analysis of antibody biosimilars using combined bottom-up and top-down hydrogen-deuterium exchange mass spectrometry.
Pan J; Zhang S; Borchers CH
Biochim Biophys Acta; 2016 Dec; 1864(12):1801-1808. PubMed ID: 27569733
[TBL] [Abstract][Full Text] [Related]
6. Similarity demonstrated between isolated charge variants of MB02, a biosimilar of bevacizumab, and Avastin® following extended physicochemical and functional characterization.
Ruppen I; Beydon ME; Solís C; Sacristán D; Vandenheede I; Ortiz A; Sandra K; Adhikary L
Biologicals; 2022 Jun; 77():1-15. PubMed ID: 35667958
[TBL] [Abstract][Full Text] [Related]
7. Nonclinical assessments of the potential biosimilar PF-06439535 and bevacizumab.
Peraza MA; Rule KE; Shiue MHI; Finch GL; Thibault S; Brown PR; Clarke DW; Leach MW
Regul Toxicol Pharmacol; 2018 Jun; 95():236-243. PubMed ID: 29574193
[TBL] [Abstract][Full Text] [Related]
8. Part 1: Physicochemical characterization of bevacizumab in undiluted 25 mg/mL drug product solutions: Comparison of originator with a biosimilar candidate.
Arvinte T; Palais C; Poirier E; Cudd A; Rajendran S; Brokx S; Dowd J
J Pharm Biomed Anal; 2019 Oct; 175():112742. PubMed ID: 31344647
[TBL] [Abstract][Full Text] [Related]
9. Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab.
Seo N; Polozova A; Zhang M; Yates Z; Cao S; Li H; Kuhns S; Maher G; McBride HJ; Liu J
MAbs; 2018; 10(4):678-691. PubMed ID: 29553864
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in structural mass spectrometry methods in the context of biosimilarity assessment: from sequence heterogeneities to higher order structures.
Castel J; Delaux S; Hernandez-Alba O; Cianférani S
J Pharm Biomed Anal; 2023 Nov; 236():115696. PubMed ID: 37713983
[TBL] [Abstract][Full Text] [Related]
11. Analytical Similarity of a Proposed Biosimilar BVZ-BC to Bevacizumab.
Yu C; Zhang F; Xu G; Wu G; Wang W; Liu C; Fu Z; Li M; Guo S; Yu X; Wang L
Anal Chem; 2020 Feb; 92(4):3161-3170. PubMed ID: 31983199
[TBL] [Abstract][Full Text] [Related]
12. Similarity demonstrated between isolated charge variants of MB02, a biosimilar of bevacizumab, and Avastin® following extended physicochemical and functional characterization.
Ruppen I; Beydon ME; Solís C; Sacristán D; Vandenheede I; Ortiz A; Sandra K; Adhikary L
Biologicals; 2021 Sep; 73():41-56. PubMed ID: 34593306
[TBL] [Abstract][Full Text] [Related]
13. Demonstrating analytical similarity of a biosimilar HLX04 to bevacizumab with a panel of state-of-the-art methods and tiering of quality attributes.
Zhang L; Yu L; Xu Y; Qin P; Shen P; Liu K; Fei M; Wang H; Cao Y; Lu L; Gao W; Zhang Z
Anal Bioanal Chem; 2023 Jul; 415(17):3341-3362. PubMed ID: 37162525
[TBL] [Abstract][Full Text] [Related]
14. A Modified Traveling Wave Ion Mobility Mass Spectrometer as a Versatile Platform for Gas-Phase Ion-Molecule Reactions.
Czar MF; Marchand A; Zenobi R
Anal Chem; 2019 May; 91(10):6624-6631. PubMed ID: 31008583
[TBL] [Abstract][Full Text] [Related]
15. Achieving multiple hydrogen/deuterium exchange timepoints of carbohydrate hydroxyls using theta-electrospray emitters.
Kim HJ; Gallagher ES
Analyst; 2020 Apr; 145(8):3056-3063. PubMed ID: 32141454
[TBL] [Abstract][Full Text] [Related]
16. Assessment of biosimilarity under native and heat-stressed conditions: rituximab, bevacizumab, and trastuzumab originators and biosimilars.
Kang J; Halseth T; Vallejo D; Najafabadi ZI; Sen KI; Ford M; Ruotolo BT; Schwendeman A
Anal Bioanal Chem; 2020 Jan; 412(3):763-775. PubMed ID: 31853605
[TBL] [Abstract][Full Text] [Related]
17. Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey.
Sheth JU; Stewart MW; Khatri M; Gupta SR; Chawla S; Rajendran A; Narayanan R
Indian J Ophthalmol; 2021 Feb; 69(2):352-356. PubMed ID: 33463590
[TBL] [Abstract][Full Text] [Related]
18. Cutting-edge mass spectrometry characterization of originator, biosimilar and biobetter antibodies.
Beck A; Debaene F; Diemer H; Wagner-Rousset E; Colas O; Van Dorsselaer A; Cianférani S
J Mass Spectrom; 2015 Feb; 50(2):285-97. PubMed ID: 25800010
[TBL] [Abstract][Full Text] [Related]
19. Multifaceted assessment of rituximab biosimilarity: The impact of glycan microheterogeneity on Fc function.
Kang J; Kim SY; Vallejo D; Hageman TS; White DR; Benet A; Coghlan J; Sen KI; Ford M; Saveliev S; Tolbert TJ; Weis DD; Schwendeman SP; Ruotolo BT; Schwendeman A
Eur J Pharm Biopharm; 2020 Jan; 146():111-124. PubMed ID: 31841688
[TBL] [Abstract][Full Text] [Related]
20. Production of monoclonal antibodies for measuring Avastin and its biosimilar by Sandwich ELISA.
Li M; An W; Wang L; Zhang F; Li J; Zhang Y; Li Y; Li H; Ren W; Zhao R; Xia C; Sun L
J Immunol Methods; 2019 Jun; 469():42-46. PubMed ID: 30943379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]